Last updated 16 days ago
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
285 patients around the world
Available in Argentina, United States, Spain
BioNTech SE
28Research sites
285Patients around the world
This study is for people with
Head and neck cancer
Squamous cell carcinoma of the head and neck
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Británico de Buenos Aires - CABA
Recruiting
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Instituto Oncológico de Córdoba IONC - Fundación Richardet Longo
Recruiting
Centro de Oncología e Investigación Buenos Aires COIBA
Recruiting
Centro de Investigación Pergamino SA
Recruiting
Instituto de Oncología de Rosario - IOR
Recruiting
Sanatorio Británico - Rosario
Recruiting
Centro Médico Caipo (centro para la atención integral de pacientes oncológicos)
Recruiting
Centro de Estudios Clínicos SAGA - CECSAGA
Recruiting
StudyAHEAD-MERIT
SponsorBioNTech SE
Study typeInterventional
Conditions
Head and neck cancerSquamous cell carcinoma of the head and neck
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04534205
